8-KLeadership Changes

ELI LILLY & Co 8-K Report, Executive Changes (Jun 2, 2009)

Filed June 2, 2009For Securities:LLY

Summary

This Form 8-K filing by Eli Lilly and Company, dated June 1, 2009, primarily announces a change in its Board of Directors. Effective June 1, 2009, R. David Hoover was elected as a new member of the Board. Mr. Hoover brings extensive executive experience, having served as Chairman, President, and CEO of Ball Corporation. His appointment is intended to bring valuable strategic and financial oversight to Lilly's board. Mr. Hoover's role on the board will include serving on the audit and compensation committees, underscoring his financial and governance expertise. His initial appointment is subject to interim election and will require shareholder approval at the 2010 annual meeting. This addition to the board signals a potential strengthening of corporate governance and strategic direction for Eli Lilly.

Key Highlights

  • 1Eli Lilly and Company appointed R. David Hoover to its Board of Directors, effective June 1, 2009.
  • 2R. David Hoover currently serves as Chairman, President, and CEO of Ball Corporation.
  • 3Hoover will serve on the Board's audit and compensation committees.
  • 4His appointment is an interim election, pending shareholder approval at the 2010 annual meeting.
  • 5Hoover has a long career with Ball Corporation, holding various leadership positions since 1970.
  • 6He brings significant executive and financial experience to the Eli Lilly board.
  • 7Hoover is also a member of the boards of Energizer Holdings, Inc., Qwest Communications International Inc., and Irwin Financial Corporation.

Frequently Asked Questions

R. David Hoover is a seasoned executive who currently serves as the Chairman, President, and Chief Executive Officer of Ball Corporation. He has a long tenure at Ball Corporation, having joined in 1970 and progressing through various leadership roles, including Chief Financial Officer and Chief Operating Officer, before assuming his current top executive positions. He also holds board positions at other public companies.

While the filing doesn't explicitly state the reasons, his appointment as a member of the audit and compensation committees suggests the board is seeking to leverage his extensive financial and executive leadership experience to enhance corporate governance and strategic oversight.

Mr. Hoover's appointment is initially an interim election. He will serve under this interim status and will be subject to a formal election by Eli Lilly shareholders at the company's annual meeting in 2010.

No, this particular Form 8-K filing is solely focused on the appointment of R. David Hoover to the Board of Directors. No other departures, elections, or appointments of officers or directors are detailed in this document.